Wegener Eric, Samuels Justin, Sidhom Mark, Trada Yuvnik, Sridharan Swetha, Dickson Samuel, McLeod Nicholas, Martin Jarad M
School of Medicine and Public Health, The University of Newcastle, Callaghan, NSW 2308, Australia.
Department of Radiation Oncology, Calvary Mater Newcastle Hospital, Waratah, NSW 2298, Australia.
Cancers (Basel). 2023 Mar 28;15(7):2018. doi: 10.3390/cancers15072018.
Prostate cancer (PC) is the most common malignancy in men. Internal radiotherapy (brachytherapy) has been used to treat PC successfully for over a century. In particular, there is level-one evidence of the benefits of using brachytherapy to escalate the dose of radiotherapy compared with standard external beam radiotherapy approaches. However, the use of PC brachytherapy is declining, despite strong evidence for its improved cancer outcomes. A method using external beam radiotherapy known as virtual high-dose-rate brachytherapy boost (vHDRB) aims to noninvasively mimic a brachytherapy boost radiation dose plan. In this review, we consider the evidence supporting brachytherapy boosts for PC and the continuing evolution of vHDRB approaches, culminating in the current generation of clinical trials, which will help define the role of this emerging modality.
前列腺癌（PC）是男性中最常见的恶性肿瘤。内放射治疗（近距离放射治疗）已成功用于治疗前列腺癌超过一个世纪。特别是，有一级证据表明与标准外照射放疗方法相比，使用近距离放射治疗提高放疗剂量具有益处。然而，尽管有强有力的证据表明前列腺癌近距离放射治疗能改善癌症治疗效果，但其使用量却在下降。一种使用外照射放疗的方法，即虚拟高剂量率近距离放射治疗增敏（vHDRB），旨在无创地模拟近距离放射治疗增敏的放射剂量计划。在本综述中，我们考量了支持前列腺癌近距离放射治疗增敏的证据以及vHDRB方法的持续演变，最终形成了当前一代的临床试验，这将有助于明确这种新兴治疗方式的作用。
